Background: Diagnosis of schizophrenia lacks of reliable medical diagnostic tests and robust biomarkers applied to clinical practice. Schizophrenic patients undergoing treatment with SGAs suffer a reduced life expectancy due to metabolic disarrangements that co-exist with their own mental illness and predispose them to develop metabolic syndrome, also exacerbated by antipsychotic treatment. Metabolomics is an emerging and potent technology able to accelerate this biomedical research. Aim: This review focus on a detailed vision of the molecular mechanisms involved both in schizophrenia and antipsychotic-induced metabolic syndrome, based on innovative metabolites that consistently change in nascent metabolic syndrome, drug-naïve, first episod...
Background. Schizophrenia is a socially significant mental illness with insufficiently studied etiol...
Although a number of proteins and genes relevant to schizophrenia have been identified in recent yea...
Purpose: To investigate the metabolic profile and biomarkers of schizophrenia with auditory hallucin...
Schizophrenia is a severe complex mental disorder affecting 0.5-1% of the world population. To date,...
BackgroundPersons with schizophrenia and other psychotic disorders have a high prevalence of obesity...
Current diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation o...
Schizophrenia (SCZ) acts as a complex and burdensome disease, in which the functional outcome can be...
Abstract Metabolomics has been attracting attention in recent years as an objective method for diagn...
Using 1H NMR-based metabolomics in association to chemometrics analysis, we analyzed here the metabo...
Primary obesity and psychotic disorders are similar with respect to the associated changes in energy...
Schizophrenia (SCZ) acts as a complex and burdensome disease, in which the functional outcome can be...
Schizophrenia (SCZ) acts as a complex and burdensome disease, in which the functional outcome can be...
Antipsychotics (APs) are the treatment cornerstone for psychotic spectrum disorders (PSDs) but have ...
Psychotic patients are at high risk for developing obesity, metabolic syndrome and type 2 diabetes. ...
BACKGROUND: Although a number of proteins and genes relevant to schizophrenia have been identified i...
Background. Schizophrenia is a socially significant mental illness with insufficiently studied etiol...
Although a number of proteins and genes relevant to schizophrenia have been identified in recent yea...
Purpose: To investigate the metabolic profile and biomarkers of schizophrenia with auditory hallucin...
Schizophrenia is a severe complex mental disorder affecting 0.5-1% of the world population. To date,...
BackgroundPersons with schizophrenia and other psychotic disorders have a high prevalence of obesity...
Current diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation o...
Schizophrenia (SCZ) acts as a complex and burdensome disease, in which the functional outcome can be...
Abstract Metabolomics has been attracting attention in recent years as an objective method for diagn...
Using 1H NMR-based metabolomics in association to chemometrics analysis, we analyzed here the metabo...
Primary obesity and psychotic disorders are similar with respect to the associated changes in energy...
Schizophrenia (SCZ) acts as a complex and burdensome disease, in which the functional outcome can be...
Schizophrenia (SCZ) acts as a complex and burdensome disease, in which the functional outcome can be...
Antipsychotics (APs) are the treatment cornerstone for psychotic spectrum disorders (PSDs) but have ...
Psychotic patients are at high risk for developing obesity, metabolic syndrome and type 2 diabetes. ...
BACKGROUND: Although a number of proteins and genes relevant to schizophrenia have been identified i...
Background. Schizophrenia is a socially significant mental illness with insufficiently studied etiol...
Although a number of proteins and genes relevant to schizophrenia have been identified in recent yea...
Purpose: To investigate the metabolic profile and biomarkers of schizophrenia with auditory hallucin...